文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺与白消安-环磷酰胺预处理对骨髓增生异常综合征或由其转化的继发性急性髓系白血病患者异基因造血干细胞移植后复发的影响:一项开放标签、多中心、随机、3期试验

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2023-01-23

该开放标签、多中心、随机3期试验在6家医院纳入202例骨髓增生异常综合征-难治性贫血伴原始细胞增多或由其转化的继发性急性髓系白血病患者,1:1随机接受粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺预处理或白消安-环磷酰胺预处理。2年累积复发率分别为10.9%和24.8%(HR 0.39,95%CI 0.19-0.79;p=0.011)。

要点

  • 2年累积复发率:粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺组10.9% vs 白消安-环磷酰胺组24.8%(HR 0.39,95%CI 0.19-0.79;p=0.011)。
  • 移植后100天内3-4级不良事件两组相似:感染34% vs 32%,急性移植物抗宿主病30% vs 30%,胃肠道毒性28% vs 29%。
  • 因不良事件死亡:粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺组11例(11%)vs 白消安-环磷酰胺组13例(13%),无治疗相关死亡。

核心结论

  • 作者认为,对于接受异基因造血干细胞移植的骨髓增生异常综合征-难治性贫血伴原始细胞增多或由其转化的继发性急性髓系白血病患者,粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺预处理是优于白消安-环磷酰胺预处理的选择。
  • 作者认为,该预处理方案可能是该患者人群的合适治疗选择。

研究设计与样本

  • 开放标签、多中心、随机、3期试验,在中国6家医院开展。
  • 纳入年龄14-65岁、骨髓增生异常综合征-难治性贫血伴原始细胞增多或由其转化的继发性急性髓系白血病、美国东部肿瘤协作组体能状态评分0-2、造血干细胞移植合并症指数0-2的患者。
  • 2016年4月18日至2019年9月30日筛查297例,202例随机1:1接受粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺预处理(n=101)或白消安-环磷酰胺预处理(n=101)。
  • 随机化采用置换区组(区组大小4),无分层,通过独立于研究 site 人员和研究者的交互式网络应答系统实施。
  • 主要终点为2年累积复发率,所有疗效和安全性终点在意向治疗人群中评估。

主要发现

  • 202例参与者中男性123例(61%),女性79例(31%);中位随访32.4个月(IQR 10.0-43.0)。
  • 2年累积复发率:粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺组10.9%(95%CI 5.8-17.9)vs 白消安-环磷酰胺组24.8%(95%CI 16.8-33.5),HR 0.39(95%CI 0.19-0.79;p=0.011)。
  • 移植后100天内3-4级不良事件:粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺组 vs 白消安-环磷酰胺组,感染34例(34%)vs 32例(32%),急性移植物抗宿主病30例(30%)vs 30例(30%),胃肠道毒性28例(28%)vs 29例(29%)。
  • 因不良事件死亡:粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺组11例(11%)vs 白消安-环磷酰胺组13例(13%);无治疗相关死亡。

关键数值与推荐

  • 粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺预处理方案:粒细胞集落刺激因子5 μg/kg每日皮下注射(第-17天至第-10天),地西他滨20 mg/m2每日静脉注射(第-14天至第-10天),白消安3.2 mg/kg每日静脉注射(第-7天至第-4天),环磷酰胺60 mg/kg每日静脉注射(第-3天和第-2天)。
  • 白消安-环磷酰胺预处理方案:白消安和环磷酰胺的剂量和持续时间与上述相同。

临床怎么用

  • 作者认为,粒细胞集落刺激因子、地西他滨联合白消安-环磷酰胺预处理可能是该患者人群合适的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relapse remains high in patients with myelodysplastic syndrome-refractory anaemia with excess blasts (RAEB) or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate whether granulocyte-colony stimulating factor (G-CSF) and decitabine plus busulfan-cyclophosphamide conditioning reduced relapse compared with busulfan-cyclophosphamide in this population. METHODS: We did an open-label, randomised, phase 3 trial at six hospitals in China. Eligible patients (aged 14-65 years) had myelodysplastic syndrome-RAEB or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome, and an Eastern Cooperative Oncology Group performance status of 0-2 and HSCT comorbidity index of 0-2. Patients were randomly assigned (1:1) to receive G-CSF, decitabine, and busulfan-cyclophosphamide conditioning or busulfan-cyclophosphamide conditioning. Randomisation was done with permuted blocks (block size four) with no stratification and was implemented through an interactive web-based response system, which was independent of study site staff and investigators. G-CSF, decitabine, and busulfan-cyclophosphamide conditioning comprised G-CSF 5 μg/kg daily subcutaneously (days -17 to -10), decitabine 20 mg/m2 daily intravenously (days -14 to -10), busulfan 3·2 mg/kg daily intravenously (days -7 to -4), and cyclophosphamide 60 mg/kg daily intravenously (days -3 and -2). Busulfan-cyclophosphamide conditioning comprised the same dose and duration of busulfan and cyclophosphamide. The primary endpoint was 2 year cumulative incidence of relapse. All efficacy and safety endpoints were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02744742; the trial is complete. FINDINGS: Between April 18, 2016, and Sept 30, 2019, 297 patients were screened for eligibility, 202 of whom were randomly assigned to G-CSF, decitabine, and busulfan-cyclophosphamide (n=101) or busulfan-cyclophosphamide (n=101) conditioning. 123 (61%) participants were male and 79 (31%) were female. Median follow-up was 32·4 months (IQR 10·0-43·0). The 2-year cumulative incidence of relapse was 10·9% (95% CI 5·8-17·9) in the G-CSF, decitabine, and busulfan-cyclophosphamide group and 24·8% (16·8-33·5) in the busulfan-cyclophosphamide group (hazard ratio 0·39 [95% CI 0·19-0·79]; p=0·011). Within 100 days after transplantation, the most common grade 3-4 adverse events in the G-CSF, decitabine, and busulfan-cyclophosphamide group and the busulfan-cyclophosphamide group were infections (34 [34%] and 32 [32%]), acute graft-versus-host disease (30 [30%] and 30 [30%]), and gastrointestinal toxicity (28 [28%] and 29 [29%]). 11 (11%) patients in the G-CSF, decitabine, and busulfan-cyclophosphamide group and 13 (13%) in the busulfan-cyclophosphamide group died of adverse events. There were no treatment related deaths. INTERPRETATION: Our results suggest that G-CSF, decitabine, and busulfan-cyclophosphamide conditioning is a better choice than busulfan-cyclophosphamide conditioning for patients with myelodysplastic syndrome-RAEB or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic HSCT. This conditioning could be a suitable therapuetic option for this patient population. FUNDING: None. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Xuan L, Dai M, Jiang E, et al. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023. PMID: 36702138. doi:10.1016/S2352-3026(22)00375-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。